Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Lifted by Finepoint Capital LP

Finepoint Capital LP boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 21.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 161,935 shares of the biotechnology company's stock after acquiring an additional 28,400 shares during the period. Sarepta Therapeutics comprises about 1.2% of Finepoint Capital LP's holdings, making the stock its 9th biggest holding. Finepoint Capital LP owned 0.17% of Sarepta Therapeutics worth $19,690,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Manchester Capital Management LLC raised its position in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after buying an additional 156 shares in the last quarter. Sunbelt Securities Inc. raised its holdings in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $36,000. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 194 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have weighed in on SRPT. Wells Fargo & Company assumed coverage on Sarepta Therapeutics in a report on Friday. They issued an "overweight" rating and a $115.00 price objective on the stock. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and cut their price objective for the company from $161.00 to $87.00 in a report on Monday, March 31st. Morgan Stanley lowered their target price on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a report on Friday. Finally, Scotiabank cut their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a report on Thursday, March 20th. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $161.83.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Stock Up 1.8 %

Shares of SRPT stock traded up $0.91 during trading on Friday, reaching $51.22. The company's stock had a trading volume of 1,643,290 shares, compared to its average volume of 1,649,001. The company has a market capitalization of $4.97 billion, a price-to-earnings ratio of 40.98 and a beta of 0.93. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 1-year low of $48.01 and a 1-year high of $173.25. The stock's 50-day moving average price is $89.37 and its 200 day moving average price is $110.71.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.